Antigen study supports, a novel method to vaccine for respiratory syncytial virus

 

Respiratory Syncytial Virus (RSV) causes dangerous respiratory disease in Humans, but previous efforts to develop a vaccine have met with disappointment and frustration.

Medical investigators have been trying to develop a vaccine for respiratory syncytial virus (RSV) for more than 51 years, without success. However, New findings point to a promising route for designing an operative vaccine. New findings by researchers at The University of California, Santa Cruz, however, point to a promising route for designing an effective vaccine.

Immune system antibodies can block the action of Respiratory Syncytial Virus and provide protection from RSV disease. A protective human antibody sticks to a folded part of the RSV G protein antigen. These new results provide a foundation for the development of a RSV vaccine.

For maximum people, RSV infection is just a bad cold, but in case of infants and older adults it can cause serious pneumonia or bronchial inflammation.

The latest research on this virus focused on the protein found on viral surface called as the RSV G glycoprotein. Scientists have isolated protective human antibodies that targeting the G glycoprotein and other collaborators at UCSC found, the atomic structure of RSV G and identified two sites of it are targeted by protective antibodies effective against a broad range of RSV strains.

The G glycoprotein is very important. It is the attachment protein that allows the virus to stick to lung cells. This virus produces a secreted form of G glycoprotein that goes out and starts flipping and distorting immune responses of an individual.

Latest invention in this field proved that these protective antibodies target to a section of the protein called as the central conserved domain that remains same for all strains of virus. The scientists determined the three-dimensional atomic structures of the binding sites of two antibodies to design a vaccine that can induce the immune system to synthesize such protective antibodies. The vaccine that is based on RSV G would have ensured that the vaccine lacks the viral protein's ability to disrupt the immune system.

Bacterial Diseases 2018 helps the researchers to discuss and learn The Hot Research Fronts and Emerging Research Fronts like this. It gives some ideas to Post-doctoral fellows to do researches in this field.